Who Paid My Doc
Injectafer
Drug Iron Deficiency Anemia
NDC 0517-0650-01
General payments
$4,996,881
Research payments
$14,669,638
Through program year 2025, $4,996,881 in general payments and $14,669,638 in research payments were reported against Injectafer (Iron Deficiency Anemia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $291,426 | 11,271 |
| 2025 | Research | $3,000 | 1 |
| 2024 | General | $830,715 | 22,332 |
| 2024 | Research | $241,947 | 11 |
| 2023 | General | $1,036,994 | 24,795 |
| 2023 | Research | $1,953,892 | 318 |
| 2022 | General | $1,220,987 | 34,824 |
| 2022 | Research | $6,268,434 | 625 |
| 2021 | General | $1,616,419 | 36,856 |
| 2021 | Research | $6,202,365 | 561 |
| 2019 | General | $341 | 12 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 100 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
130,090 general · 1,516 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.